Because hearts with a temporally induced knockout of acyl-CoA synthetase 1 (Acsl1 T2/2 ) are virtually unable to oxidize fatty acids, glucose use increases 8-fold to compensate. This metabolic switch activates mechanistic target of rapamycin complex 1 (mTORC1), which initiates growth by increasing protein and RNA synthesis and fatty acid metabolism, while decreasing autophagy. Compared with controls, Acsl1 T2/2 hearts contained 3 times more mitochondria with abnormal structure and displayed a 35-43% lower respiratory function. To study the effects of mTORC1 activation on mitochondrial structure and function, mTORC1 was inhibited by treating Acsl1 T2/2 and littermate control mice with rapamycin or vehicle alone for 2 wk. Rapamycin treatment normalized mitochondrial structure, number, and the maximal respiration rate in Acsl1 T2/2 hearts, but did not improve ADP-stimulated oxygen consumption, which was likely caused by the 33-51% lower ATP synthase activity present in both vehicle-and rapamycintreated Acsl1 T2/2 hearts. The turnover of microtubule associated protein light chain 3b in Acsl1 T2/2 hearts was 88% lower than controls, indicating a diminished rate of autophagy. Rapamycin treatment increased autophagy to a rate that was 3.1-fold higher than in controls, allowing the formation of autophagolysosomes and the clearance of damaged mitochondria. Thus, long-chain acyl-CoA synthetase isoform 1 (ACSL1) deficiency in the heart activated mTORC1, thereby inhibiting autophagy and increasing the number of damaged mitochondria.-Grevengoed, T. J., Cooper, D. E., Young, P. A., Ellis, J. M., Coleman, R. A. Loss of long-chain acyl-CoA synthetase isoform 1 impairs cardiac autophagy and mitochondrial structure through mechanistic target of rapamycin complex 1 activation. FASEB J. 29, 4641-4653 (2015). www.fasebj.orgThe heart alters its substrate use to meet the constant high demand for energy. For example, whereas the heart normally obtains 60-90% of its energy from very LDL-derived fatty acids (1), feeding or hypoxia can increase the use of glucose, whereas fasting can increase the use of amino acids and ketone bodies (2). In diabetes, the impaired uptake of glucose increases the use of fatty acids (3, 4), and conversely, glucose use increases with both heart failure and the pathologic hypertrophy caused by pressure overload (5-8). Because it is unclear whether the switch in substrate use in each of these states is compensatory or pathologic, we asked whether predominant glucose use, in the absence of other cardiac dysfunction, would be detrimental.Acyl-CoA synthetases (ACSLs) convert fatty acids to acylCoAs, which can then be oxidized in the mitochondria to produce energy, incorporated into triacylglycerol (TAG) for storage, or incorporated into phospholipids for membrane biogenesis. Of the 5 long-chain mammalian ACSL isoforms, long-chain acyl-CoA synthetase isoform 1 (ACSL1) is the major isoform in the heart, accounting for 90% of total ACSL activity. In the temporally induced mouse model deficient in ACSL isof...